WeLeader Biomedical reported that June 2026 consolidated revenue reached NT$113 million (US$3.52 million), its second-highest monthly level on record, as Taiwan’s health screening demand and diagnostics shipments continued to rise. The company said the result marked the fourth consecutive month above NT$100 million and extended its year-on-year revenue growth streak to 17 months.